Elomaa I, Taube T, Blomqvist C, Rissanen P, Rannikko S, Alfthan O
Department of Radiotherapy, Helsinki University Central Hospital, Finland.
Eur Urol. 1988;14(2):104-6. doi: 10.1159/000472913.
Aminoglutethimide (AG) and hydrocortisone (HC) were given to 20 patients with advanced prostatic cancer resistant to conventional hormonal therapy. Most patients had painful bone metastases and were heavily pretreated. 12 of 16 patients required narcotic analgetics. 8 of 20 were bedridden. AG + HC produced relief of bone pain in 12 patients (75%) and only 4 required narcotics after treatment. The performance status improved in 8 of 20 patients (40%). However, the number of bone metastases seen in bone scans decreased in only 4 patients (22%). The level of serum alkaline phosphatase decreased in 11 of 18 patients and that of acid phosphatase in 8 of 16 patients. The reduction of bone pain lasted approximately 4 months (range 1-15 months). The median lifespan between the start of AG treatment and death was 8 months (range 2-22 months). There was no difference in survival between responders and nonresponders. 3 patients had skin rash, 1 lethargy and 1 thrombocytopenia.
对20例对传统激素治疗耐药的晚期前列腺癌患者给予氨鲁米特（AG）和氢化可的松（HC）。大多数患者有疼痛性骨转移，且之前接受过大量治疗。16例患者中有12例需要使用麻醉性镇痛药。20例中有8例卧床不起。AG + HC使12例患者（75%）的骨痛得到缓解，治疗后只有4例需要使用麻醉性镇痛药。20例患者中有8例（40%）的身体状况得到改善。然而，骨扫描显示骨转移数量仅在4例患者（22%）中减少。18例患者中有11例血清碱性磷酸酶水平下降，16例患者中有8例酸性磷酸酶水平下降。骨痛缓解持续约4个月（范围1 - 15个月）。从开始AG治疗到死亡的中位生存期为8个月（范围2 - 22个月）。反应者和无反应者的生存率没有差异。3例患者出现皮疹，1例嗜睡，1例血小板减少。
